Dollars & Sense: Economic Analysis Helps Erbitux Win NICE OK For Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Serono finally gets approval from NICE for Erbitux as a first-line treatment for colorectal cancer – thanks to a revised economic analysis and a rebate scheme.